We serve Chemical Name:[4-(2-pyrrolidin-1-ylethylcarbamoyl)phenyl]boronic acid,hydrochloride CAS:957060-70-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![[4-(2-pyrrolidin-1-ylethylcarbamoyl)phenyl]boronic acid,hydrochloride](https://a.dearchem.com/CAS2/957060-70-7.png)
Chemical Name:[4-(2-pyrrolidin-1-ylethylcarbamoyl)phenyl]boronic acid,hydrochloride
CAS.NO:957060-70-7
Synonyms:or3264
Molecular Formula:C13H20BClN2O3
Molecular Weight:298.57400
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:72.80000
Exact Mass:298.12600
LogP:0.32280
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like or3264 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,or3264 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,or3264 Use and application,or3264 technical grade,usp/ep/jp grade.
Related News: While reactions requiring the use of metal catalysts may necessitate heating to temperatures of 160oC, and/or cooling to -60oC or lower, enzyme-catalyzed reactions instead run at temperatures in the region of ~10 – 40oC. 5-(3-methylphenyl)pyridin-2-amine,dihydrochloride manufacturers The QbD studies were designed concisely to minimize the use of the API and evaluate the critical product parameters that could affect the product quality attributes of the drug product, per FDA’s QbD guidance. Metralindole suppliers “The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said. methyl (1s,4r)-4-(hydroxymethyl)cyclopent-2-ene-1-carboxylate vendor & factory This scheme has a total outlay of Rs. 6,940 crore for the entire period. The applications under four different target segments were invited on November 30, 2020. Of the 215 applications, 36 products across the 4 target segments were granted. ,“The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said.
